Choosing manufacturing partners for the steps you will not do yourself: what a fill finish cdmo has to demonstrate in sterile fill-finish before a batch is scheduled and why that capability is scarcer than bulk capacity, how a cdmo partner is judged on quality systems and slot reliability rather than on price, what the question of what is cdmo in pharma is really asking about who owns the process, where a cdmo pharma company, a biologics cmo, biologic manufacturing generally and active pharmaceutical ingredient manufacturing sit as different capabilities under one word, what adc manufacturers must add in containment and cleaning verification, and where a protein synthesis company fits for material that is not made biologically

Selecting a partner

1. Name the capability, not the category. Bulk manufacture, sterile filling, potent handling and chemical synthesis are different plants. A partner excellent at one may subcontract another, which changes accountability and lead time.
2. Treat sterile filling as the scarce step. Filling capacity with the right container formats and the right containment is frequently harder to book than bulk capacity, and it sits at the end of the timeline where delay is most expensive.
3. Assess the quality system, not the equipment list. Deviation handling, change control, data integrity and the last inspection outcome predict batch success better than any equipment inventory. Ask to see the systems, not the suite.
4. Establish who owns the process. A platform partner runs their process and gives speed at the cost of portability. A contract manufacturer runs yours. Both are valid and the difference decides whether you can ever move.
5. Confirm containment for potent payloads. Highly potent material requires containment engineering, occupational exposure monitoring and cleaning verification between products. Not every biologics site can take that work, and it narrows the list early.
6. Negotiate failure and reslot before signing. What happens when a batch fails release, who pays, how quickly a slot reopens and what data you receive. These terms are far easier to agree before a campaign than during one.

The scarce step sets the timeline

Programmes plan around bulk manufacture and are delayed by filling, analytics or release testing. Identifying the scarce step for your specific product and booking it first is the most effective schedule protection available.

Ask each candidate which step is their constraint. The honest ones will tell you, and the answer is more useful than a capacity brochure.

Quality systems predict outcomes

How a site handles a deviation, controls a change and manages its records predicts whether your batch will be released. Equipment lists predict very little, because everyone has similar equipment.

Audit the systems, read the inspection history, and speak to a reference customer at a similar scale.

Common questions

Why is filling harder to book than bulk?

Because sterile filling suites are fewer, are shared across many products, and require format specific change over and validation. It is the step where timelines most often slip.

What separates a good partner from a cheap one?

The quality system and slot reliability. A failed batch or a missed slot costs far more than the difference in price, and both are predicted by deviation handling and inspection history rather than by equipment.

Can a process be moved between partners?

Only if you own it and it was documented to transfer. Platform processes generally are not portable, which is a reasonable trade to make knowingly and a painful one to discover.

Browse by service class

• Compare Gene synthesis on advertised prices